This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
XXB 750 is an experimental injected drug that targets natriuretic peptide (NPR1) and is developed to treat resistant hypertension.[1][2] It was also tried for heart failure with reduced ejection fraction.[3]
^Janakiraman, Arun; Cohen, Debbie L. (27 September 2023). "New Potential Treatments for Resistant Hypertension". Current Cardiology Reports. doi:10.1007/s11886-023-01966-8.
^"XXB 750 - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.
^"Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)". Retrieved 23 November 2023.
XXB750 is an experimental injected drug that targets natriuretic peptide (NPR1) and is developed to treat resistant hypertension. It was also tried for...
Mercury and Jupiter engines, later variants could produce 1,000 horsepower (750 kilowatts) from its capacity of 1,750 cubic inches (28 L) by use of a geared...
and early 1950s. Predecessor of the nonode approach XXB – Medium-mu twin triode, also numbered 3C6/XXB XXD – Medium-mu twin triode, also numbered 14AF7/XXD...